AstraZeneca Shares Rise for Fourth Day as Trading Volume Hits 176th Rank

AstraZeneca (AZN) shares rose 0.03% on April 25, 2025, marking the fourth consecutive day of gains, with a total increase of 3.99% over the past four days. The company's trading volume reached 4.61 billion, ranking 176th in the day's market activity.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Camurus' Oczyesa for the treatment of acromegaly. This positive recommendation is a significant milestone for Camurus, as it brings the product one step closer to market authorization in the European Union.

AstraZeneca also received a positive opinion from the CHMP on a marketing authorization variation for Calquence. This decision supports the continued use of Calquence in treating certain types of cancer, reinforcing AstraZeneca's position in the oncology market.

Additionally, AstraZeneca's monoclonal antibody tezepelumab has received Phase III approval in India. This approval, granted by the Central Drugs Standard Control Organization (CDSCO), allows for the treatment of severe asthma, further expanding the drug's global reach and market potential.